Clinical Trials Directory

Trials / Completed

CompletedNCT00724555

Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities

Status
Completed
Phase
Study type
Observational
Enrollment
2,005 (estimated)
Sponsor
Georgetown University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to increase treatment of acute stroke with tissue plasminogen activator (tPA) across the District of Columbia. This study, however, will not evaluate tPA as an intervention.

Detailed description

There are a number of well-known barriers to receiving tissue plasminogen activator (tPA) including transit time to hospital, paramedic and provider training, tPA standing orders, and provider guidelines. Among underserved populations, limited stroke knowledge, socioculturally determined attitudes, and beliefs and myths held by community members may serve as additional barriers that hinder these populations from receiving tPA and acute stroke care. Targeted multilevel interventions designed to overcome specific barriers may significantly increase the number of individuals with stroke who are appropriately treated with intravenous tPA (IV tPA) in underserved communities. Identification of the specific components of healthcare interventions that are the most effective is critical to improve delivery of acute stroke therapy. The goal of this study is to learn more about public knowledge, attitudes, beliefs and perceptions regarding stroke and stroke treatment in order to identify sociocultural and environmental barriers to receiving tPA and acute stroke care in an underserved community. This study will also determine if implementation of a multilevel intervention program can significantly increase the number of people with ischemic stroke who are appropriately treated with IV tPA in a predominantly underserved community. In the study, researchers will evaluate the different levels of the intervention to determine which efforts are most effective.

Conditions

Timeline

Start date
2008-02-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2008-07-29
Last updated
2014-01-31

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00724555. Inclusion in this directory is not an endorsement.